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Various adenine nucleotides activated phospholipase C of FRTL-5 cell membranes in the following order of activity, 
ATPTS > ATP > AppNp > AppCp = ADP > MeSATP. This order was well consistent with that observed in intact 
cells. Such activation occurred only in the presence of appropriate concentrations of GTPyS and Ca 2+ , in a way similar 
to the norepinephrine-induced activation. NaF, a non-specific GTP-binding protein (G-protein) activator, also stimulated 
the enzyme. These adenine nucleotides, norepinephrine and NaF-induced activations were inhibited by GDPflS. We con- 
clude that a G-protein is involved in the adenine nucleotides-induced activation of phospholipase C via P~-purinergic 
receptor in FRTL-5 cells. 
Purinergic receptor, P2-; GTP-binding protein; Phospholipase C; (FRTL-5 cell) 
1. INTRODUCTION 
Recent publications have shown that the recep- 
tors for Ca2+-mobilizing hormones are linked to 
the activation of phospholipase C through a GTP- 
binding protein (G-protein), based on the fact that 
GTP or its derivatives synergize those hormones in 
the activation of the enzyme [1-3]. The G-protein 
which activates phospholipase C has been termed 
Gp [2]. Extracellular ATP and related compounds 
have recently been found, via P2-purinergic recep- 
tor, to stimulate phospholipase C and to cause in- 
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ositol phosphate formation in many types of cells 
[4-10] including FRTL-5 thyroid ceils [11-14]. 
In the present paper, we studied the P2-receptor- 
mediated activation of phospholipase C in a cell- 
free membrane preparation of FRTL-5 cells. We 
used mainly nonhydrolyzable P2-agonists uch as 
AppNp and AppCp instead of ATP, in order to 
avoid a possible participation of the agonists in the 
production of phosphatidylinositol 4,5-bisphos- 
phate (PIP2), the substrate of phospholipase C, by 
phosphorylating phosphatidylinositol 4-phosphate 
(PIP). These P2-agonists activated phospholipase 
C in a GTP 7 S- and Ca2+-dependent manner in the 
same way as norepinephrine, an Crl-adrenergic 
receptor agonist [15,16], did, proving that Gp is 
involved in the P2-receptor-mediated phospholi- 
pase C activation in FRTL-5 thyroid ceils. 
Abbreviations: AppNp, 5 '-adenylylimidodiphosphate; AppCp, 
~',7-methyleneadenosine 5'-triphosphate; GTPTS, guanosine 
5'-O-(3-thiotriphosphate); GDP~S, guanosine 5'-O-(2-thio- 
diphosphate); ATPTS, adenosine 5'-O-(3-thiotriphosphate); 
ADPBS, adenosine 5'-O-(2-thiodiphosphate); MeSATP, 
2-methylthioadenosine 5' -triphosphate 
2. MATERIALS AND METHODS 
2.1. Materials 
AppNp, AppCp, ATP and ADP were purchased from 
Sigma; GTPyS, GDP~'S, ATPyS and ADP~S were from Boeh- 
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ringer Mannheim; MeSATP was from Research Biochemicals 
Inc.; myo-[2-aH]inositol (23 Ci/mmol) was from American 
Radiolabeled Chemicals Inc. The sources of all other reagents 
used were those described in [4,11-13,16]. 
2.2. Cell culture 
FRTL-5 thyroid cells, a cell line derived from normal rat 
thyroid [17] was provided by Interthyr Research Foundation 
(Baltimore, MD). The cells were grown in 12-well plates (for 
measuring [3H]inositol phosphates production i  intact cells) or 
10-cm culture dishes (for preparing membrane fractions) as 
described in [12,14,16]. The culture medium was changed to 
Ham's 10 medium containing [3H]inositol (2.5/,Ci in l-ml 
medium) and 5070 calf serum with a six-hormone mixture as 
described in [16] and maintained for further 2 days. 
2.3. 13H]Inositol phosphates production in intact cells 
In figs 3C and 4B, [3H]inositol phosphates production from 
intact cells in response to norepinephrine (NE) and various 
Pz-agonists was measured as described in [11,14,16]. 
2.4. Membrane preparation and assay of phospholipase C 
The cells cultured with [aH]inositol were washed twice with 
PBS containing 1 mM EGTA and scraped with a rubber 
policeman. The cells were washed once more with PBS, 
suspended in 50 mM Hepes (pH 7.4) containing 50 mM 
sucrose, 1 mM EGTA and 100 U/ml aprotinin, then 
homogenized in a Physcotron homogenizer (NS-310E, Niti-on, 
Tokyo, Japan) for 20 s, and centrifuged at500 x g for 10 rain. 
The supernatant was recentrifuged at 10000 x g for 15 min and 
the resultant pellet was used as crude plasma membranes. These 
membranes (-100/zg protein), containing 5 x 105 dpm in 
100/d, were incubated at 37°C for 10 min (in a final volume of 
200/tl) with 500/zM CaC12 (unless otherwise specified), 1mM 
EGTA, 50 mM sucrose, 100 U/ml of aprotinin, 2.5 mM 
MgCl2, 100 mM KC1, 10 mM LiC1, 0.1 mg/ml of bovine serum 
albumin, 50 mM Hepes (pH 7.4) and various agents tested. Free 
Ca 2+ concentration was measured by Quin 2 fluorescence and 
was approximately 50nM under these conditions. The reaction 
was terminated by adding first 1 ml of CHCIa/MeOH/HCI 
(100: 100: l) and afterwards 0.3 ml of H20.3H-labeled inositol 
phosphate (IP), inositol bisphosphate (IP2) and inositol 
trisphosphate (IPa) were separated as described in [11]. The IP3 
fraction contains both IP3(1,4,5) and IP3(1,3,4). Data were nor- 
realized to 5 x 105 dpm of the radioactivity in membranes. 
3. RESULTS AND DISCUSSION 
Fig. 1 shows the formation of IP, IP2 and IP3 by 
3H-labeled membranes incubated with GTPTS, 
AppNp, NE or their combinations in the presence 
of the indicated concentration of free Ca 2+. The 
inositol phosphate formation, reflecting 
phospholipase C activation, was increased with the 
increase in Ca 2+ concentration either in the 
presence or absence of additives (fig.lA-F). A 
half-maximal effective concentration (ECso) of 
Ca 2+ was about 10/zM in all the cases without any 
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Fig.1. Ca2+-dependent phospholipase C activity. 3H-labeled 
membranes were incubated with no addition (0), 0.1/zM 
GTPTS (v), 10/zM GTPTS (e), 1/zM norepinephrine (NE) 
(A), 1/zM NE plus 0.1/zM GTPg, S (A), 100/tM AppNp (n), 
and 100/zM AppNp plus 0.1/zM GTPg, S (m) in the presence of 
the indicated free Ca 2+ concentration. Results were the mean of 
two separate xperiments. The difference in the value between 
two experiments was less than 10070 of the mean value. 
addition. 10/zM GTPTS activated the enzyme only 
when the Ca 2+ level was physiological or lower 
(10-100 nM), but did not at the higher Ca 2+ level 
(100/zM-1 raM). Thus, GTPTS lowered the effec- 
tive Ca 2+ concentration for enzyme activation. The 
results were essentially similar to those reported 
with other types of cells (see for reviews [1,2]) as 
well as FRTL-5 cells [18,19], in terms of a guanine 
nucleotide-dependent activation. This suggests the 
involvement of a G-protein, Gv, in the regulation 
of phospholipase C activity in such a way that Gp 
increases the sensitivity of the enzyme to Ca 2+. 
As shown in f ig.lD-F, this cell-free system was 
not activated by the addition of 100/zM AppNp, a 
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P2-agonist nor by 1/zM NE in the absence of the 
GTP derivative. Moreover, the GTPTS-induced 
activation was not appreciable at 0.1/~M of the 
nucleotide (f ig. lA-C).  Ho~vever, in the presence 
of this low dose (0.1/~M) of the nucleotide, these 
agonists induced a phospholipase C activation, in 
a manner similar to the high GTPTS concentra- 
tion; the rate of activation was very high at a 
physiological level of free Ca 2÷ (f ig. lD-F).  
In fig.2, we examined in detail the AppNp- 
induced activation of phospholipase C at a sub- 
physiological level of Ca 2÷ (50 nM) where no ap- 
preciable Ca 2÷ effect was observed. GTPTS alone 
increased the enzyme activity in a dose-dependent 
manner. In consistency with the results shown in 
fig.l, 100/zM AppNp potentiated the GTPTS ac- 
tion in the low dose range of GTPTS 
(3 nM-1/~M), although AppNp never changed the 
maximum level of GTPTS-induced phospholipase 
C, presumably because the enzyme activity was 
already fully activated at such high concentrations 
of GTPTS. Thus, AppNp decreased ECso for the 
GTPTS-induced activation from around 1/zM to 
around 50 nM. This AppNp action was quite 
similar to the NE action on GTPTS-induced 
phospholipase C (data not shown). These results 
support the idea that the AppNp stimulation of 
P2-receptors as well as the NE stimulation of 
a~-receptors of FRTL-5 cell membranes induce 
phospholipase C activation via Gp in a manner 
analogous to the Gs-dependent activation of 
receptor-coupled a enylate cyclase [3]. 
The involvement of G-protein (Gp) in the 
P2-agonists' activation of phospholipase C was 
further supported by the experiments hown in 
fig.3. A non-specific G-protein activator, NaF (in 
the presence of AIC13) activated the enzyme in the 
absence of guanine nucleotide. This NaF-induced 
activation was significantly inhibited by a GDP 
derivative, GDPflS (fig.3A). On the other hand, 
the inhibition rate was decreased with the increase 
in NaF concentration; the percentage inhibition in 
the presence of 1 mM GDPflS was 880-/0, 59°'/0, and 
37o70 when 0.5 mM, 1 mM, and 5 mM NaF was 
added, respectively. The results suggest that 
GDPflS competitively inhibited the NaF-induced 
action. The GDP derivative also inhibited the en- 
zyme activation in response to either AppNp or NE 
(fig.3B). In these cases, GDPflS probably acts at a 
transducer (Gp) level rather than a receptor level, 
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Fig.2. Effect of AppNp on GTPyS-induced phospholipase 
activity. 3H-labeled membranes were incubated with (e) or 
without .(o) 100/zM AppNp in the presence of the indicated 
dose of GTPTS. Results were the mean _+ SE of three separate 
experiments. 
since this guanine nucleotide failed to affect both 
AppNp and NE-induced inositol phosphate pro- 
duction in intact cells (fig.3C). 
In the foregoing experiments, we used AppNp as 
a nonhydrolyzable ATP derivative instead of 
ATP, to analyze P2-receptor agonist actions in a 
cell-free system. In all the experiments, AppNp 
behaved similarly to NE as a receptor agonist 
which activated phospholipase C, without con- 
tradicting the idea that AppNp acts as an agonist 
for a purinergic, probably a P2-purinergic recep- 
tor. To confirm further the receptor subtype, the 
effect of various adenine nucleotides known as 
P2-agonists on phospholipase C activity was ex- 
amined in the present cell-free system (fig.4A) and 
compared with the results obtained in intact 
FRTL-5 ceils (fig.4B). In the cell-free system, the 
order of magnitude of the responses to these 
purine nucleotides at concentrations tested was 
ATPTS > ATP > AppNp > AppCp = ADP > 
MeSATP > ADP~S, although we could not com- 
pare their accurate potency or efficacy because of 
the unsaturated ose-response curves under the 
conditions employed (fig.4A). This rank order was 
well consistent with that obtained in intact cells 
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Fig.3. Effect of GDP~S on NaF, NE or AppNp-induced 
phospholipase C in membrane fractions (A and B) or in intact 
cells (C). 3H-labeled membranes were incubated with the 
indicated concentration of NaF plus 10/zM A1CI3 in A, and 
with no addition (o), 0.1/~M GTP (o), 0.1/zM (3TP plus 1/zM 
NE (A) or 0.1/zM GTP plus 300gM AppNp (B) in B, in the 
presence of the indicated ose of GDP~5~5. IP2 + IP3 were 
measured. In C, 3H-labeled cells were incubated for 30 rain 
with 1 #M NE (A) or 300 aM AppNp (m) in the presence ofthe 
indicated ose of GDP~S. Total inositol phosphates (IP + 
IP2 + IP3) were measured. In the absence of GDPBS, inositol 
phosphate formation was increased from 4860 =i= 360 
(dpm/well) to 35820 + 1230 and 81690 ± 1893 by NE and 
AppNp, respectively. Data were expressed as percentage of
these activities elicited by these agents. Results were the mean + 
SE of at least hree separate xperiments in each case. 
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Fig.4. Dose-dependent activation of phospholipase C as 
induced by P2-agonists in membranes (A) and in intact cells (B). 
In A, 3H-labeled membranes were incubated with the indicated 
concentration f ATP-yS (A), ATP (o), AppNp (A), AppCp 
(V), ADP (o), MeSATP (m) or ADP/5'S (m) in the presence of 
0.1 ,~M GTPTS. The increment in activity as induced by these 
Pz-agonists was shown. The activity obtained by GTPTS alone 
was 0.72 (dpm × 10-3). In B, 3H-labeled cells were incubated 
for 30 rain with various P2-agonists. The formation of total 
inositol phosphates (IP + IP2 + IP~) was measured, and results 
were expressed as percentage of the control value (without 
P~-agonist). The control value was 2973 dpm/well. Symbols 
were the same as those shown in A. Results in A and B were the 
mean of two separate experiments. The difference in the value 
between two experiments was less than 10070 of the mean value. 
(fig.4B). Adenosine or its derivative, phenyliso- 
propyladenosine known as Pl-agonists was ineffec- 
tive in the activation of the enzyme both in 
membranes and in intact cells (data not shown). 
Summariz ing the above results, in FRTL-5 
thyroid cells, their stimulated P2-purinergic recep- 
tors as well as a radrenerg ic  receptors activate 
phospholipase C with the aid of Gp. An  involve- 
ment of Gp in the regulation of P2-receptor- 
coupled phospholipase C has recently been sug- 
gested also in turkey erythrocyte membranes [20]. 
However, in these avian erythrocyte membranes 
[20], MeSATP and ADP/5~S were more potent han 
ATP ,  whereas in FRTL-5 cell membranes these 
nucleotides were very weak agonists, suggesting 
the presence of two P2-receptors both l inked to 
phospholipase C via Gp but with different phar- 
macological specificities, just like fl-adrenergic 
135 
Volume 253, number 1,2 FEBS LETTERS August 1989 
receptor subtypes, ~1- and ~Y2-subtype, both of 
which are l inked to adenylate cyclase via the same 
G-protein, Gs. This would suggest a great variety 
of P2-receptor subtypes than those previously pro- 
posed by us: two types of PE-receptors, one cou- 
pling to phospholipase C and the other coupling to 
adenylate cyclase via Gi [4], and by others [21]. 
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